Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIq-ai Ltd Regulatory News (IQAI)

Share Price Information for Iq-ai Ltd (IQAI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.65
Bid: 1.60
Ask: 1.70
Change: 0.00 (0.00%)
Spread: 0.10 (6.25%)
Open: 1.65
High: 1.65
Low: 1.65
Prev. Close: 1.65
IQAI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

StoneChecker signs agreement with Korea ISG

6 Mar 2018 07:00

RNS Number : 7562G
Flying Brands Limited
06 March 2018
 

Flying Brands PLC

("Flying Brands" or the "Company")

StoneChecker Software Limited signs an Exclusive Marketing and Distributor Agreement for the commercialisation of StoneChecker software in South Korea with Korea Computer Motion ISG

Flying Brands PLC (AIM: FBDU), the medical services and software company, is pleased to announce that its subsidiary StoneChecker Software Ltd ("SC") has signed an Exclusive Marketing and Distributor arrangement with Korea Computer Motion ISG ("Korea ISG") based in Seoul, South Korea, for sales and distribution of its StoneChecker® Kidney Stone analysis software ("StoneChecker").

StoneChecker will be used by hospitals, imaging and urology centres for diagnosing and assessing kidney stones, on non-contrast CT scans, in the clinical setting in South Korea.

The incidence of kidney stone disease is on the rise in South Korea. It is estimated that out of a total population of approximately 51 million people, there are about 300,000 new cases of kidney stone disease each year. The Board of Flying Brands consider that by utilising the StoneChecker software, a significant portion of the estimated US $50million spent on conducting failed lithotripsies in South Korea each year, could be saved.

Mr Nick Stevens, CEO of StoneChecker said "We are pleased to sign this significant Distributorship agreement with Korea ISG to support the expansion of StoneChecker in the rapidly growing and important South Korean medical imaging market. We are confident that by working with an experienced team led by the CEO Jacob Woo, who has a great understanding of the market and customer base, we stand to increase StoneChecker's revenue potential, market reach and meet our customers' needs."

Mr Jacob Woo, CEO of Korea ISG commented, "We are pleased to have started to work with SC this year to promote the innovative StoneChecker kidney-stone analysis software on CT in South Korea which addresses a big gap in the urology-radiology market and has great clinical utility. StoneChecker is already attracting a lot of interest amongst the top university hospitals around the world and in South Korea (potential-customers). I anticipate a very successful business relationship and rapidly increasing StoneChecker software sales. Our team has a first-class reputation amongst radiologists and clinicians in the region, and offers unrivalled in-depth market-access and know-how in South Korea."

About Stone Checker Software Ltd.

Stone Checker Software Ltd is owned by Flying Brands PLC, based in Chilcompton, Radstock, UK. SC focusses on the development and supply of advanced kidney stone analysis software - StoneChecker, for analysis of renal calculi and for easy interpretation of imaging data.

The StoneChecker Software uses sophisticated statistical techniques to make detailed analyses of kidney stones. The software produces a series of important data in a quick and efficient way to describe key clinical stone variables such as stone volume and measures of stone heterogeneity.

About Korea Motion ISG

Korea ISG has installed and supported MRI/CT 3D processing imaging software to about 120 prominent Korean hospitals for 23 years, and a prominent medical imaging software distribution (sales and service/support) company in South Korea. They are experienced distributors of medical software from other world leading suppliers, with a wide customer base.

The Directors of the Company accept responsibility for the contents of this announcement.

For further information, please contact:

Flying Brands Limited

Qu Li/Trevor Brown/Vinod Kaushal

Tel: 020 7469 0930

 

 

Peterhouse Corporate Finance (Financial Adviser and Broker)

Lucy Williams/Heena Karani

Tel: 020 7220 9797

 

 

 

-Ends-

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STRJAMRTMBIMBIP
Date   Source Headline
2nd May 202412:47 pmRNSIB Announces Expanded Access Program for GaM
29th Apr 20243:26 pmRNSPublication of Annual Report
5th Mar 20247:00 amRNSGrant of Options
1st Mar 20248:22 amRNSHolding(s) in Company
1st Mar 20248:20 amRNSHolding(s) in Company
26th Feb 20247:00 amRNSResult of Broker Option and Total Voting Rights
22nd Feb 20247:00 amRNSPlacing and Broker Option
9th Feb 202412:49 pmRNSFDA Application Update
2nd Feb 20248:39 amRNSIB awarded a $100,000 grant
22nd Jan 202410:05 amRNSHolding(s) in Company
15th Jan 20247:01 amRNSDirector Dealings and Conversion of CLNs
15th Jan 20247:00 amRNSHolding(s) in Company
10th Jan 20247:00 amRNSIB Launching an Expanded Access Program for GaM
19th Dec 20232:29 pmRNSImaging Biometrics granted FDA “Fast-Track”
5th Dec 202310:58 amRNSIQ-AI Announces Positive Interim Phase 1 Results
20th Nov 20231:42 pmRNSHolding(s) in Company
9th Nov 202311:38 amRNSDirector Dealing and Conversion of CLNs
8th Nov 202310:59 amRNSApplication for Pediatric Rare Disease Designation
6th Nov 20231:02 pmRNSHolding(s) in Company
18th Oct 20232:29 pmRNSUpdate Regarding Imaging Biometrics LLC
13th Oct 20238:55 amRNSIB Letter to Shareholders
9th Oct 20237:00 amRNSOrphan Drug Status to GaM and Total Voting Rights
3rd Oct 202311:30 amRNSHolding(s) in Company
19th Sep 20232:32 pmRNSIQ-AI shares cease trading on the OTCQB
8th Sep 20237:00 amRNSReduced Gadolinium Approach Validated'
18th Aug 202312:06 pmRNSUpdate on Collaboration Agreement with Mayo Clinic
18th Aug 202311:20 amRNSIB & GE HealthCare Enter into Commercial Agreement
17th Aug 20237:00 amRNSHalf-year Report
19th Jul 20237:00 amRNSImaging Biometrics Installs IB Nimble™ For MCW
13th Jul 20237:00 amRNSOrphan Drug Designation for GaM in Pediatric GBM
27th Jun 20237:00 amRNSStudies Show GaM Inhibits Pediatric Tumor Growth
23rd May 202311:02 amRNSResult of AGM
23rd May 20237:00 amRNSAGM Statement
3rd May 20234:14 pmRNSNotice of AGM
26th Apr 20237:00 amRNSFinal Results
28th Feb 20233:52 pmRNSOrphan Drug Designation Status
13th Jan 20232:05 pmRNSSecond Price Monitoring Extn
13th Jan 20232:00 pmRNSPrice Monitoring Extension
13th Jan 202311:05 amRNSSecond Price Monitoring Extn
13th Jan 202311:00 amRNSPrice Monitoring Extension
10th Jan 20237:00 amRNSLetter to Shareholders
2nd Dec 202211:11 amRNSHolding in Company
25th Oct 202211:00 amRNSPrice Monitoring Extension
30th Sep 20227:00 amRNSLetter to Shareholders
26th Sep 20227:00 amRNSIssue of Warrants to Employees
16th Aug 20224:40 pmRNSSecond Price Monitoring Extn
16th Aug 20224:35 pmRNSPrice Monitoring Extension
16th Aug 20229:28 amRNSHalf-year Report
3rd Aug 20221:01 pmRNSTR1 - Notification of Major Holdings
11th Jul 20227:00 amRNSImaging Biometrics Announces Channel Partnership

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.